Conference Coverage
Conference Coverage
Promising topline phase 2 results for novel oral Alzheimer’s drug
The data suggest that a “high plasma pTau-217/non–pTau-217 ratio, a marker of AD pathology, likely defines an AD population responsive to T3D-959...
Conference Coverage
‘Frame running’ may help boost physical activity in MS
‘Frame running’ uses a three-wheeled frame with a saddle and body supports but no pedals to allow individuals with disabilities and balance...
Conference Coverage
MS, DMTs, and pregnancy: Beware of over-caution regarding treatment
Don’t be too quick to stop therapy or too slow to restart it, researcher tells ECTRIMS audience.
Conference Coverage
Wearable devices show promise in monitoring multiple sclerosis
Further analysis may allow the prediction of “relevant changes throughout the course of multiple sclerosis.”
Conference Coverage
Playing board games may slow cognitive decline, improve QoL
Playing a board game involves concentration, strategy, and intermittent rewards – all of which are good for the brain and may involve the...
Conference Coverage
NMO: Study says double diagnoses with MS are common
Nearly half of patients with coding for NMO were also listed as having MS – a very similar condition.
Conference Coverage
EBV and MS: Just how deep is the link?
Two MS researchers disagree over how tightly they’re connected, and one says “second hit” may be factor.
Conference Coverage
Stem cell transplants in early MS: Who benefits most?
Neurologists outline findings as the MS field works toward consensus on HSCT as rescue therapy.
Conference Coverage
MS-tailored weight loss program achieves meaningful results
Weight loss “was associated with improved mobility, reduced fatigability, and improved physical quality of life.”
Conference Coverage
‘We’re halfway home’: UCSF’s Dr. Stephen Hauser sketches MS future
Identification of a reliable MS biomarker as well as early detection and intervention will be key going forward.
Conference Coverage
Next up in MS trials: More insight into progressive disease
Results from several treatment trials in progressive MS are expected over the next 2 years.